Explanipedia

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study Open

Koji Izutsu, Mitsumasa Watanabe, Tomomi Toubai, Taku Tsukamoto, Dai Maruyama , et al. · 2025

This phase 2 study (NCT05105841) evaluated the safety and efficacy of a fixed-duration 12-cycle regimen of venetoclax plus obinutuzumab in Japanese patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic …

Safety profiles in elderly patients with DLBCL on first-line Pola-R-CHP: a claims database study in Japan Open

Yo Saito, Takeshi Oda, S Nakanishi, Masaki Ota, Naoki Maeda , et al. · 2025

Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) is approved for the treatment of untreated diffuse large B-cell lymphoma (DLBCL); however, safety data in patients aged ≥80 years remai…

Plain language summary about tirabrutinib in relapsed/refractory primary central nervous system lymphoma Open

Kazuhiko Sugiyama, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui , et al. · 2025

What is this summary about?

Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies Open

Hisayuki Yokoyama, Noriko Fukuhara, Koji Ando, Hiroatsu Iida, Takahiro Yamauchi , et al. · 2025

Rogocekib (development name CTX-712) is a first-in-class, orally available, highly potent, and selective small molecule inhibitor of CDC2-like kinase (CLK), a key regulator of the RNA splicing process. Preclinical studies demonstrated anti…

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma Open

Hideki Goto, Satoshi Ito, Masahiro Kizaki, Masaki Yamaguchi, Noriko Fukuhara , et al. · 2025

Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE Open

Yuko Mishima, Daigo Hashimoto, Michiko Ichii, Noriko Fukuhara, Toshiki Uchida , et al. · 2025

The Impact of Tirabrutinib Monotherapy for the Treatment of Bing‐Neel Syndrome: A Multicenter Retrospective Study Open

Masuho Saburi, Taro Masunari, Noriko Fukuhara, Yuichiro Inagaki, Arika Shimura , et al. · 2025

231 | IMPACT OF RITUXIMAB EARLY ADMINISTRATION ON OUTCOMES IN ADVANCED STAGE LOW TUMOR BURDEN FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF PHASE III JCOG1411/FLORA STUDY Open

Dai Maruyama, Noriko Fukuhara, Kenichi Ishizawa, Yusuke Sano, Ryunosuke Machida , et al. · 2025

290 | REAL‐WORLD SAFETY AND EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: ANALYSIS OF 500 PATIENTS IN THE POLASTAR STUDY Open

Naoki Nakamura, Shinya Rai, H Sawa, Kohta Miyawaki, Atsushi� Satake , et al. · 2025

65 | UTILITY OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR EXTRANODAL NK/T‐CELL LYMPHOMA Open

Ayumi Fujimoto, Tatsuhiko Anzai, Koji Kato, Junji Suzumiya, Tomoko Fukuda , et al. · 2025

Protocol for a multicentre, open-label, dose-escalation phase I/II study evaluating the tolerability, safety, efficacy and pharmacokinetics of repeated continuous intravenous PPMX-T003 in patients with aggressive natural killer cell leukaemia Open

Noriko Fukuhara, Makoto Onizuka, Junya Kanda, Noboru Asada, Koji Kato , et al. · 2025

Introduction Aggressive natural killer cell leukaemia (ANKL) is a rare form of NK cell lymphoma with a very low incidence and poor prognosis. While multi-agent chemotherapy including L-asparaginase has been used to treat ANKL patients, the…

240 | EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES AT 3‐YEAR FOLLOW‐UP IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA Open

Kim Linton, Julie M. Vose, Wojciech Jurczak, Pieternella J. Lugtenburg, Emmanuel Gyan , et al. · 2025

570 | EFFICACY AND SAFETY OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA Open

Dai Maruyama, Yuko Mishima, Takahiro Kumode, Junya Kuroda, Nobuhiro Kanemura , et al. · 2025

Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial Open

Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima , et al. · 2025

Background Primary results from the EPCORE NHL-3 trial (NCT04542824) showed deep, durable responses in Japanese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with single-agent epcoritamab, a subcu…

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma Open

Noriko Fukuhara, Isao Yoshida, Takuro Ishiguro, Katsuya Fujimoto, Junya Kuroda , et al. · 2025

Follicular lymphoma (FL) is the second most common subtype of non‐Hodgkin lymphoma (NHL) in Japan, the United States, and Western Europe. Parsaclisib is a potent, selective next‐generation PI3Kδ inhibitor that has demonstrated clinical eff…

Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study) Open

Tsutomu Kobayashi, Kenichi Ishizawa, Ryunosuke Machida, Ryo Sadachi, Keita Sasaki , et al. · 2025

Maintenance therapy with monoclonal anti-CD20 antibody is the standard approach in patients with follicular lymphoma who initially treated and achieved response to immunochemotherapy. Maintenance therapy reduces the risk of lymphoma progre…

Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study Open

Ayumi Fujimoto, Kana Miyazaki, Kimikazu Yakushijin, Takahiro Fujino, Wataru Munakata , et al. · 2025

Treatments and Outcomes of Newly Diagnosed CD5‐Positive Diffuse Large B‐Cell Lymphoma: A Multi‐Institutional Observational Study Open

Yuma Nato, Kana Miyazaki, Dai Maruyama, Hiroyuki Takahashi, Kazutaka Sunami , et al. · 2025

CD5‐positive diffuse large B‐cell lymphoma (CD5+ DLBCL) is characterized by a poor prognosis and frequent central nervous system (CNS) relapse. Sandwich therapy comprising dose‐adjusted (DA)‐EPOCH‐R (etoposide, prednisolone, vincristine, c…

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial Open

Kazuyuki Shimada, Motoko Yamaguchi, Yachiyo Kuwatsuka, Kosei Matsue, Keijiro Sato , et al. · 2025

A phase II study of zandelisib in patients with relapsed or refractory indolent non‐Hodgkin lymphoma: ME‐401‐K02 study Open

Wataru Munakata, Takahiro Kumode, Hideki Goto, Noriko Fukuhara, Tatsu Shimoyama , et al. · 2025

Summary Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zand…

Mixed-phenotype acute leukemia with trilineage differentiation presenting as a non-leukemic mediastinal tumor Open

Satoshi Ichikawa, Maya Yamato, SUSUMU HATTA, Koichi Onodera, Noriko Fukuhara , et al. · 2025

Mixed-phenotype acute leukemia (MPAL) is an uncommon hematological malignancy, and cases exhibiting trilineage differentiation are extraordinarily rare. Here, we report the case of a 63-year-old male patient who presented with severe dyspn…

Successful Allogeneic Hematopoietic Stem Cell Transplantation for Nodal Epstein-Barr Virus-positive T/NK-cell Lymphoma Open

Satoshi Ichikawa, Hiroaki Abe, Naoya Morota, Akihisa Kawajiri, Ryo Nakagawa , et al. · 2024

Nodal Epstein-Barr virus-positive T/NK-cell lymphoma (EB-nTNKL) is an extremely rare disease characterized by an aggressive clinical course and poor prognosis, for which treatment strategies have not yet been established. We herein report …

Angioimmunoblastic T-cell lymphoma harboring a t(8;14)(q24;q11.2)/TCR::MYC translocation that presented with intestinal infiltration Open

Satoshi Ichikawa, Hiroki Kato, Naoya Morota, Hiroaki Abe, Akihisa Kawajiri , et al. · 2024

Although rearrangement of the MYC oncogene (MYC-R) is frequently observed in aggressive B-cell lymphomas, it is extremely rare in T-cell malignancies. A 64-year-old man who had been under observation for several years because of asymptomat…

Successful Cord Blood Transplantation for Myeloid/Natural Killer Precursor Acute Leukemia: A Case Report and Literature Review Open

Satoshi Ichikawa, Hiroaki Abe, Hiroka Komatsu, Kenta Takenaka, Hiroshi Nakamura , et al. · 2024

A 21-year-old man was diagnosed with myeloid/natural killer precursor leukemia (MNKPL) with bone marrow infiltration of blasts of cyCD3⁺, CD7⁺, CD33⁺, CD34^dim, CD56^+/-, HLA-DR⁺

Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305) Open

Shigeru Kusumoto, Wataru Munakata, Ryunosuke Machida, Takashi Terauchi, Hiroaki Onaya , et al. · 2024

This single‐arm confirmatory study (JCOG1305) aimed to evaluate the utility of interim positron emission tomography (iPET)‐guided therapy for newly diagnosed advanced‐stage classic Hodgkin lymphoma (cHL). Patients aged 16–60 years with cHL…

Plasma Venetoclax Concentrations in Patients with Acute Myeloid Leukemia Treated with CYP3A4 Inhibitors Open

Ayaka Otsuki, Masaki Kumondai, Daisuke Kobayashi, Masafumi Kikuchi, Yugo Ueki , et al. · 2024

Venetoclax (VEN) is used in patients with acute myeloid leukemia (AML) and is primarily metabolized by CYP3A4, a major drug-metabolizing enzyme. Patients with AML simultaneously administered VEN and CYP3A4 inhibitors require a more appropr…

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study Open

Jehan Dupuis, Emmanuel Bachy, Franck Morschhauser, Guillaume Cartron, Noriko Fukuhara , et al. · 2024

Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma Open

Hajime Yonezawa, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui , et al. · 2024

Background The ONO-4059-02 phase 1/2 study showed favorable efficacy and acceptable safety profile of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, for relapsed/refractory primary central nervous system lymphoma (PC…

Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin’s lymphoma Open

Tatsuo Oyake, Takahiro Maeta, Takenori Takahata, Yoshiko Tamai, Yoshihiro Kameoka , et al. · 2024

Immune checkpoint inhibitors (ICI) are promising therapeutic agents for relapsed or refractory classical Hodgkin's lymphoma (RRcHL). This retrospective study evaluated patients with RRcHL registered in the clinical research program Tohoku-…

Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan Open

Motoko Yamaguchi, Noriko Fukuhara, Jun Takizawa, Kenji Ishitsuka, Akihiko Yokohama , et al. · 2024

Alemtuzumab is recommended as first-line and second-line therapies for T-cell prolymphocytic leukemia (T-PLL). This study retrospectively evaluated the efficacy and safety of alemtuzumab in nine Japanese patients with T-PLL at five partici…

Noriko Fukuhara YOU? Author Swipe